These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21937987)

  • 21. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
    Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
    Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma.
    Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
    Drug Metab Dispos; 2011 Apr; 39(4):591-602. PubMed ID: 21212240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
    Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
    Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.
    Han B; Mao J; Chien JY; Hall SD
    Drug Metab Dispos; 2013 Jul; 41(7):1329-38. PubMed ID: 23584886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?
    Friedman EJ; Fraser IP; Wang YH; Bergman AJ; Li CC; Larson PJ; Chodakewitz J; Wagner JA; Stoch SA
    J Clin Pharmacol; 2011 Nov; 51(11):1561-70. PubMed ID: 21209240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
    Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
    Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
    J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in CYP3A activity using intravenous and oral midazolam.
    Chen M; Ma L; Drusano GL; Bertino JS; Nafziger AN
    Clin Pharmacol Ther; 2006 Nov; 80(5):531-8. PubMed ID: 17112809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
    Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
    Nassar YM; Hohmann N; Michelet R; Gottwalt K; Meid AD; Burhenne J; Huisinga W; Haefeli WE; Mikus G; Kloft C
    Clin Pharmacokinet; 2022 Nov; 61(11):1595-1607. PubMed ID: 36195807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
    Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
    Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentration effect relationship of CYP3A inhibition by ritonavir in humans.
    Eichbaum C; Cortese M; Blank A; Burhenne J; Mikus G
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1795-800. PubMed ID: 23748748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
    Stoll F; Burhenne J; Lausecker B; Weiss J; Thomsen T; Haefeli WE; Mikus G
    J Clin Pharmacol; 2013 Nov; 53(11):1199-204. PubMed ID: 23939663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.
    Calvert H; Twelves C; Ranson M; Plummer R; Fettner S; Pantze M; Ling J; Hamilton M; Lum BL; Rakhit A
    Anticancer Drugs; 2014 Aug; 25(7):832-40. PubMed ID: 24637575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A limited sampling strategy of phenotyping probe midazolam to predict inhibited activities of hepatic CYP3A in rats].
    Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
    Yao Xue Xue Bao; 2008 Sep; 43(9):905-11. PubMed ID: 19048780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.